EUVIMEDEUVIMED entdecken
Leserbrief

Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management

Kevin Hoffman, Malak Husseinali, Vicky Ren

Journal of the American Academy of Dermatology · 2026-09

DOI: 10.1016/j.jaad.2026.09.045 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the American Academy of Dermatology, 2026-09. Verfasst von Kevin Hoffman und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: kevin.hoffman@bcm.edu. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 agonistethicsinterdisciplinary carepsoriasisscope of practice

Autor:innen und Institutionen

  • School of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: kevin.hoffman@bcm.edu.
  • School of Medicine, Baylor College of Medicine, Houston, Texas.
  • Department of Dermatology, Baylor College of Medicine, Houston, Texas.

Zitieren

APA

Hoffman, K., Husseinali, M., & Ren, V. (2026). Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.09.045

Vancouver

Hoffman K, Husseinali M, Ren V. Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.09.045

BibTeX
@article{Hoffman2026,
  author = {Hoffman, Kevin and Husseinali, Malak and Ren, Vicky},
  title = {Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  doi = {10.1016/j.jaad.2026.09.045}
}
Kostenlos starten →